Potential of atypical antipsychotics in the treatment of nonpsychotic disorders

CNS Drugs

Volumn 9, Issue 3, 1998, Pages 213-232

  Potenza, Marc N ^a,b   McDougle, Christopher J ^c  

^a Yale University School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CLOZAPINE; NEUROLEPTIC AGENT; REMOXIPRIDE; RISPERIDONE; SERTRALINE; TRAZODONE; VALPROIC ACID;

AGGRESSION; AKATHISIA; CARDIOTOXICITY; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPOTENSION; NOCTURNAL ENURESIS; OBSESSION; PRIORITY JOURNAL; REVIEW; RHINITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TIC; TRICHOTILLOMANIA; VERTIGO; WEIGHT GAIN;

EID: 0031957772     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809030-00005     Document Type: Review

References (165)

1. Pachter M. A clinical evaluation of chlorpromazine in chronic schizophrenics. Am J Psychiatry 1957; 113: 931
2. Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ. editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1277-86
3. Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press, 1991: 1-13
4. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs: a review of compounds in use and development. Br J Psychiatry 1993; 163 Suppl. 22: 7-18
5. Baldessarini R, Frankenburg FR. Clozapine: a novel atypical antipsychotic agent. N Engl J Med 1991; 324: 746-54
6. Lessen JE, Gommeren W, Eens A, et al. The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247: 661-70
7. Wadworth AM, Heel RC. Remoxipride: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs 1990; 40: 8631-79
8. Saller CF, Salalma AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285-92
9. Moore NA, Tye NC, Axton MS, et al. The hehavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 1992; 262: 545-51
10. Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurons in the rat. Eur J Pharmacol 1990; 182: 613-4
11. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 1983; 40: 1235-40
12. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989; 46: 722-30
13. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 652-4
14. McDougle CJ, Goodman WK. Obsessive compulsive disorder: recent neurobiological developments. Curr Opin Psychiatry 1990; 3: 239-44
15. McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive compulsive disorder: implications for treatment and pathogenesis. Psychiatr Clin North Am 1993; 16 (4): 749-66
16. Carpenter L, McDougle CJ, Epperson CN, et al. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf 1996: 15(2): 116-34
17. McDougle CJ, Goodman WK. Combination pharmacological treatment strategies. In: Hollander E, Stein D, editors. Obsessive-compulsive disorders: etiology, diagnosis, and treatment. New York: Marcel Decker, Inc., 1997: 203-23
18. McDougle CJ. Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11: 175-84
19. McDougle CJ, Goodman WK, Price LH. The pharmacotherapy of obsessive compulsive disorder. Pharmacopsychiatry 1993; 26 Suppl.: 24-9
20. Goodman WK, McDougle CJ, Price LH, et al. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990; 51: 36-43
21. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302-8
22. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum OCD. J Clin Psychiatry 1994; 55 (3 Suppl.): 24-31
23. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive compulsive disorder. Am J Psychiatry 1995; 152: 1812-4
24. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 423-9
25. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive compulsive disorder: three cases. J Clin Psychiatry 1995; 56: 526-8
26. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996; 57: 303- 6
27. Ravizza L, Barzega G, Bellino S, et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996; 32: 677-82
28. Young CR, Bostic JQ, McDanald CL. Clozapine and refractory obsessive-compulsive disorder: a case report. J Clin Psychopharmacol 1994; 14: 209-10
29. Baker RW, Chengappa KNR, Baird JW, et al. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Pyschiatry 1992; 53 (12): 439-42
30. Patil VJ. Development ot transient obsessive-compulsive symptoms during treatment with clozapine [letter]. Am J Psychiatry 1992; 149: 272
31. Cassady SL, Thaker GK. Addition of fluoxetine to clozapine [letter]. Am J Psychiatry 1992; 149 (9): 1274
32. Hwang MY, Stein D, Simeon D, et al. Clozapine, obsessive symptoms and serotonergic mechanisms [letter]. Am J Psychiatry 1993; 150: 1435
33. Steingard S, Chengappa KNR, Baker RW, et al. Clozapine, obsessive symptoms, and serotonergic mechanisms [letter]. Am J Psychiatry 1993; 150 (9): 1435
34. Buckley PF, Schulz SC. Obsessive-compulsive symptoms and clozapine [letter]. Br J Psychiatry 1994; 165: 408
35. Eales MJ, Layeni AO. Exacerbation of obsessive-compulsive symptoms associated with clozapine. Br J Psychiatry 1994; 164: 687-8
36. LaPorta LD. More on obsessive-compulsive symptoms and clozapine [leller]. J Clin Psychiatry 1994; 55 (7): 312
37. Dursun SM, Reveley MA. Obsessive-compulsive symptoms and clozapine [letter]. Br J Psychiatry 1994; 165: 267-8
38. Levin Z, Hwang MY, Rotrosen J. The relationship between clozapine and obsessive-compulsive disorder [letter]. Compr Psychiatry 1996; 37: 74
39. McDougle CJ, Epperson CN, Price LH. Obsessive-compulsive symptoms with neuroleptics [letter]. J Am Acad Child Adolesc Psychiatry 1996; 35: 837
40. Baker RB, Chengappa KNR, Steingard S, et al. More on obsessive-compulsive symptoms and clozapine [letter]. J Clin Psychiatry 1994; 55: 312
41. Patel B, Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment [letter]. Am J Psychiatry 1993; 150 (5): 836
42. Allen L, Tejera C. Treatmenl of clozapine-induced obsessive-compulsive symptoms with sertraline [letter]. Am J Psychiatry 1994; 151: 1096-7
43. Ghaemi SN, Zarate Jr CA, Popli AP, et al. Is there a relationship between clozapine and obsessive-compulsive disorder? A retrospective chart review. Compr Psychiatry 1995; 36 (4): 267-70
44. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Pt I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-11
45. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Pt II. Validity. Arch Gen Psychiatry 1989; 46: 1012-6
46. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54 Suppl. 9: 14-34
47. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia [letter]. Am J Psychiatry 1994; 151: (11): 1714-5
48. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms [letter]. J Clin Psychopharmacol 1994; 14: 358-9
49. Toren P, Samuel E, Weizman R, et al. Case study: emergence of transient compulsive symptoms during treatment with clothiapine. J Am Acad Child Adol Psychiatry 1995; 34: 1469-72
50. McDougle CJ, Price LH, Volkmar FR. Recent advances in the pharmacotherapy of autism and related conditions. In: Volkmar FR. editor. Psychoses and pervasive developmental disorders. Philadelphia: W.B. Saunders, 1994: 71-89
51. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6: 177-90
52. McDougle CJ, Naylor ST, Cohen CJ, et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 993-1000
53. McDougle CJ, Naylor ST, Cohen DJ, et al. A double-blind, placebo-contolled study of fluvoxamine in adults with antistic disorder. Arch Gen Psychiatry 1996; 53: 1001-8
54. Campbell M, Adams P, Perry R, et al. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 1988; 24: 251-5
55. Zuddas V, Ledda MG, Fratta A, et al. Clinical effects of clozapine on autistic disorder [letter]. Am J Psychiatry 1996; 153: 738
56. McDougle CJ, Brodkin ES, Yeung PP, et al. Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 1995; 5 (4): 273-82
57. Demb HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities [letter]. J Child Adolesc Psychopharmacol 1996; 6 (1): 79-80
58. Hardan A, Johnson K, Johnson C, et al. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35: 1551-6
59. Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 1994; 32: 721-9
60. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36 (5): 685-93
61. Purdon SE, Lit W, Labelle A, et al. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994; 39: 400-5
62. Simeon JG, Carrey NJ, Wiggins DM, et al. Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychopharmacol 1995; 5 (1): 69-79
63. Fisman S, Steele M, Short J, et al. Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry 1996; 35 (7); 937-40
64. Megens AAHP, Niemegeers CJE, Awouters FHL. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol. J Pharmacol Exp Ther 1992; 260: 160-7
65. Dixon AK, Huber C, Lowe DA. Clozapine promotes approachoriented behavior in male mice. J Clin Psychiatry 1994; 55(9) Suppl. Br: 4-7
66. Prinssen EPM, Ellenbrock BA, Cools AR. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 1994; 262: 167-70
67. Corbett R, Hartman H, Kerman LL, et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 1993; 45: 9-17
68. Peterson BS. Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. J Clin Psychiatry 1996; 57 Suppl 9: 24-34
69. Cohen DJ, Leckman JF. Developmental psychopathology and neurobiology of Tourette's syndrome. J Am Acad Child Adol Psychiatry 1994; 33: 2-15
70. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136: 317-20
71. van del Linden C, Bruggeman R, van Woerkom TCAM. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone [letter]. Mov Disord 1944; 9 (6): 687-8
72. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J am Acad Child Adolesc Psychiatry 1995; 34 (9): 1147-52
73. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996; 57: 29-31
74. Buitelaar JK, Cohen-Kettenis P, Vlutters H, et al. Remoxipride in adolescents with Tourette's syndrome: an open pilot study. J Child Adolesc Psychopharmacol 1995; 5: 121-8
75. Shulman LM, Singer C, Wenier WJ. Risperidone in Gilles de la Tourette syndrome [letter]. Neurology 1995; 45: 1419
76. Diantoniis MR, Henry KM, Partridge PAH, et al. Tics and risperidone [letter]. J Am Acad Child Adolesc Psychiatry 1996; 35: 839-40
77. Scahill L, Lombroso PJ, King RA, et al. Tics and risperidone [letter]. J Am Acad Child Adolesc Psychiatry 1996; 35: 840
78. Giakis WJ. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 1097-8
79. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 4th ed. Washington. DC: American Psychiatric Association, 1994
80. Swedo SE, Leonard HL. Trichotillomania: an obsessive-compulsive spectrum disorder? Psychiatric Clin North Am 1992; 15: 777-90
81. King RA, Scahill L, Vitulano L, et al. Childhood trichotillomania: clinical phenomenology, comorbidity, and family genetics. J Am Acad Child Adolesc Psychiatry 1995; 34: 1451-9
82. Winchel RM, Jones JS, Stanley B, et al. Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry 1992; 53: 304-8
83. Koran LM, Ringold A, Hewlett W. Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull 1992; 28: 145-9
84. Christenson GA, Mackenzie TB, Mitchell JE, et al. A placebo-controlled, double-blind crussover study of fluoxetine in tichotillomania. Am J Psychiatry 1991; 148: 1566-71
85. Streichenwein SM, Thornby JI. A Long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 1995; 152: 1192-6
86. Stein DJ, Hollander E. Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 1992; 53: 123-6
87. Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15: 243-9
88. Volavka J. Neurobiology of violence. Washington, DC: American Psychiatric Press, 1995
89. McNiel DE, Binder RL, Greenfield TK. Predictors of violence in civilly committed acute psychiatric patients. Am J Psychiatry 1988; 145: 965-70
90. Rossi AM, Jacobs M, Monteleone M, et al. Characteristics of psychiatric patients who engage in assaultive or other fear-inducing behaviors. J Nerv Ment Dis 1986; 174: 154-60
91. Craig TJ. An epidemiologic study of problems associated with violence among psychiatric inpatients. Am J Psychiatry 1982; 139: 1262-6
92. Krakowski MI, Kunz M, Czobor P, et al. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry 1993; 44: 640-4
93. Van Putten T, Mutalipassi LR, Malkin MD. Phenothiazine-induced decompensation. Arch Gen Psychiatry 1974; 30: 102-5
94. Yudofsky SC, Silver JM, Schneider SE. Pharmacologic treatment of aggression. Psychiatr Ann 1987; 17: 397-407
95. Ratey JJ, Gordon A. The psychopharmacology of aggression: toward a new day. Psychopharmacol Bull 1993; 29: 65-73
96. Medalia A, Gold J, Merriam AE. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988; 3: 249-71
97. Eichelman B. Aggressive behavior: from the laboratory to clinic. Quo vadit? Arch Gen Psychiatry 1992; 49: 488-92
98. Sánchez C, Arnt J, Hyttel J, et al. The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology 1993; 110: 53-9
99. Wilson WH. Clinical review of clozapine treatment in a state hospital. Hosp Community Psychiatry 1992; 43: 700-3
100. Volavka J, Zito JM, Vitral J, et al. Clozapine effects on hostility and aggression in schizophrenia [letter]. J Clin Psychopharmacol 1993; 13: 287-9
101. Ratey JJ, Leveroni C, Kilmer D, et al. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 1993; 54: 219-23
102. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995; 23: 607-11
103. Michals ML, Crismon ML, Roberts S, et al. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 1993; 13: 198-203
104. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402-5
105. Vanden Borre R, Vermote R, Buttiëns M, et al. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1993; 87: 167-71
106. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated aggression [letter]. Am J Psychiatry 1995; 152: 1239
107. Bellus SB, Stewart D, Kost PP. Clozapine in aggression [letter]. Psychiatr Serv 1995; 46: 187
108. Goldberg RJ, Goldberg JS. Low-dose risperidone for dementia-related disturbed behavior in nursing homes [abstract NR262: 126]. New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association: 1995 May 23; Miami
109. Sunderland T. Treatment of the elderly suffering from psychosis and dementia. J Clin Psychiatry 1996; 57 Suppl. 9: 53-6
110. Cross-National Collaborative Panic Study - Second Phase Investigators. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992; 160: 191-202
111. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine in mania. Proceedings of the 32nd Annual Meeting of the American College of Neuropsychopharmacology; 1993 Dec. 150
112. Calabrese JR, Meltzer HY, Markovitz PJ. Clozapine prophylaxis in rapid cycling bipolar disorder [letter]. J Clin Psychopharmacol 1991; 11: 396-7
113. Suppes T, McElroy SL, Gilbert J, et al. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992; 32: 270-80
114. Bocchetta A, Bernardi F, Burrai C, et al. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 1993; 88: 434-9
115. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121-4
116. Privitera MR, Lamberti JS, Maharaj K. Clozapine in a bipolar depressed patient [letter]. Am J Psychiatry 1993; 150: 986
117. Dassa D, Kaladjian A, Azorin JM, et al. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 1993; 163: 822-4
118. Keck Jr PE, McElroy SL, Strakowski SM, et al. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology 1994; 114: 529-38
119. Suppes T, Phillips KA, Judd CR. Clozapine treatment of non-psychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994; 36: 338-40
120. Hopkins HS, Gelenberg AJ. Treatment of bipolar disorder: how far have we come? Psychopharmacol Bull 1994; 30: 27-38
121. Kimmel SE, Calabrese JR, Woyshville MJ, et al. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry 1994; 55 (9 Suppl. B): 91-3
122. Banov MD, Zarate Jr CA, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295-300
123. Dwight MM, Keck Jr PE, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder [letter]. Lancet 1994; 344: 554-5
124. Fuchs DC. Clozapine treatment of bipolar disorder in a young adolescent. J Am Acad Child Adolesc Psychiatry 1994; 33: 1299-302
125. Calabrese JR, Woyshville MJ. A medication algorithm for treatment of bipolar rapid cycling? J Clin Psychiatry 1995; 56 Suppl. 3: 11-8
126. Zarate Jr CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411-7
127. Zarate Jr CA, Tohen M, Banov MD, et al. Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56: 108-12
128. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated wirh schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56: 514-8
129. Azorin J-M. Long-term treatment of mood disorders in schizophrenia. Acta Psychiatr Scand 1995; 91 Suppl. 388: 20-3
130. Diaz SF. Mania associated with risperidone use [letter]. J Clin Psychiatry 1996; 57: 41-2
131. Goodnick PJ. Risperidone treatment of refractory acute mania [letter]. J Clin Psychiatry 1995; 56: 431-2
132. Koek RJ, Kessler CC. Probable induction of mania by risperidone [letter]. J Clin Psychiatry 1996; 57: 174-5
133. Tohen M, Zarate Jr CA, Centorrino F, et al. Risperidone in the treatment of mabia. J Clin Psychiatry 1996; 57: 249-53
134. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-64
135. Keck Jr PE, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995; 56: 466-70
136. Schaffer CB, Schaffer LC. The use of risperidone in the treatment of bipolar disorder [letter]. J Clin Psychiatry 1996; 57: 136
137. Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996; 57 Suppl. 9: 44-52
138. Keck Jr PE, McElroy SL, Strakowski SM. New development in the pharmacologic treatment of schizoaffective disorder. J Clin Psychiatry 1996; 57 Suppl. 9: 41-8
139. Marder SR. Clinical experience with risperidone. J Clin Psychiatry 1996: 57 Suppl. 9: 57-61
140. Bonuccclli U, Ceravolo R, Maremmani C, et al. Clozapine in Huntington's chorea. Neurology 1994; 44: 821-3
141. Safferman AZ, Kane JM, Aronowitz JS, et al.The use of clozapine in neurologic disorders. J Clin Psychiatry 1994; 55 (9 Suppl. B): 98-101
142. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5: 225-9
143. Bennet Jr JP, Landov ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551-5
144. Bennett Jr JP, Landow ER, Dietrich S, et al. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994; 9: 409-14
145. Tolosa ES, Valldeoriola F, Marti MJ. New and emerging strategies for improving levodopa treatment. Neurology 1994; 44 Suppl. 6: S35-44
146. Klockgether T, Löschmann P-A, Wüllner U. New medical and surgical treatments for Parkinson's disease. Curr Opin Neurol 1994; 7: 346-52
147. Pfeiffer C, Wagner ML. Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 1994; 51: 3047-53
148. Jansen ENH. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994; 89: 262-5
149. Gross R, Amital D. Clozapine in the treatment of tremor in Parkinson's disease [letter]. Acta Neurol Scand 1995; 91: 225
150. Fitzgerald K, Devakumar M. Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1995; 58: 392
151. Ghadirian AM, Annable L, Bélanger MC, et al. A cross sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 1996; 57: 22-8
152. Lieberman J, Saltz B, Johns C, et al. Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 1989; 25: 57-62
153. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503-10
154. Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. J Nerv Ment Dis 1993; 181: 649-51
155. Richter A, Löscher W. The atypical neuroleptic, clozapine, exerts a antidystonic activity in a mutant hamster model: comparison with haloperidol. Eur J Pharmacol 1993; 242: 309-12
156. Russo DT, Bunch CL. Tardive dyskinesia revisited. Am H Health Syst Pharm 1995; 52: 2137-8
157. Songer DA, Schulte HM. Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine [letter]. J Clin Psychiatry 1996; 57: 40
158. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases. Mov Disord 1994; 9 (3): 321-4
159. Van Harten PN, Kamphuis DJ, Matroos GE. Use of clozapine in tardive dystonia. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 263-74
160. Lang AE, Sandor P, Duff J. Remosipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol 1995; 18 (1): 39-45
161. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994; 55 (9 Suppl. B): 107-9
162. Barak Y, Wittenberg N, Stein D, et al. Clozapine and tardive dyskinesia: analysis of clinical trials. Ann Neurol 1995; 38 (6): 972-3
163. Ayd Jr FJ. Clozapine efficacy in treating tardive dyskinesia. Int Drug Therapy Newslett 1996; 31(7):25-6
164. Jaffe E, Trémeau F, Sharif Z, et al. Clozapine in tardive Tourette syndrome. Biol Psychiatry 1995; 38: 196-7
165. Levin H, Chengappa R, Kambhampati RK, et al. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53: 248-51